- Home
- SOS vs MDXH Comparison
SOS vs MDXH Comparison
Compare SOS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SOS | MDXH |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 21.1M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOS | MDXH |
|---|---|---|
| Price | $0.98 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 60.6K | ★ 15.5M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $0.40 |
| 52 Week High | $2.48 | $5.33 |
Technical Indicators
Market Signals| Indicator | SOS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 64.95 |
| Support Level | $0.93 | $0.68 |
| Resistance Level | $1.12 | $1.13 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 70.21 | 44.03 |
Price Performance
Historical ComparisonAbout SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.